Skip to Content
  • AMPK: Time To Think Hard

    AMP-activated protein kinase, now that’s an enzyme for you. It sits at the center of a cell’s metabolic switchboard, and if you’re talking abo… Read More
  • How Long, Oh Lord, How Long?

    Here we have the prototypical slow summer day. So I’m going to use this one to throw a question out to the readership: those of you in preclinical drug di… Read More
  • A Long Journey to the Capsid

    There’s a fine article at C&E News on Gilead’s capsid inhibitor for HIV. For those not into virology, the capsid is the protein coat that viruse… Read More
  • Following Up

    Here’s a question that I’m not sure if there’s a general answer to: if you’re putting together a drug discovery portfolio, what percenta… Read More
  • Thinking About Genetics and Disease

    Robert Plenge has an excellent post here, drawing on this recent paper from authors at Stanford. It’s on the idea of polygenic traits and disease, a very… Read More
  • Thoughts on An Antibody Failure

    Talking with some drug discovery folks the other day, I said “You know, if you don’t hold your breath when your compound goes into tox testing, you… Read More
Page 1 of 5312345...102030...Last »